Vivos Therapeutics, Inc. develops and commercializes medical technology and healthcare services for breathing-related sleep disorders, including obstructive sleep apnea and snoring associated with dentofacial abnormalities. Its Complete Airway Repositioning and Expansion (CARE) oral devices have FDA 510(k) clearances for adult OSA patients across severity levels and for moderate-to-severe OSA in children ages 6 to 17.
Company news commonly covers financial results, sleep testing services, treatment-center activity, and the integration of The Sleep Center of Nevada operating assets. Updates also address the shift toward a medical-affiliation distribution model, payer-network status for supported professional practices, collaborations for airway and sleep technologies, and capital actions such as warrant exercises and private placements.
Vivos Therapeutics (Nasdaq: VVOS) received Nasdaq confirmation that it currently meets the minimum stockholders’ equity requirement for continued listing. The October 20, 2026 letter confirmed compliance with Rule 5550(b)(1), which requires at least $2.5 million in equity.
Vivos previously closed its acquisition of an 11% fully diluted equity interest in SOD Sciences and 50% co-ownership of SOD’s pseudohypoxia early-warning test. It issued 12,000 Series C preferred shares with $12 million aggregate stated value, convertible at $0.15 into up to 80 million common shares. Conversion is subject to a 19.99% exchange cap pending stockholder approval to lift it and an initial 4.99% beneficial ownership limit.
Vivos expects an equity increase exceeding $10 million, subject to final purchase price accounting and independent accountant review. Failure to demonstrate compliance in its next periodic report could lead to delisting.
Vivos Therapeutics (Nasdaq: VVOS) closed its acquisition of an 11% fully diluted stake in SOD Sciences and co-ownership of its pseudohypoxia test. Vivos acquired a 50% undivided interest in the test and related intellectual property, with rights to half its contribution margin across sales channels. It issued 12,000 Series C preferred shares with a $12 million stated value; neither party paid cash. The preferred shares convert at $0.15 into up to 80 million common shares, subject to limits.
Vivos expects more than $10 million in additional stockholders’ equity, subject to valuation and auditor review; Nasdaq compliance remains subject to Nasdaq review. Planned marketing arrangements could provide access to AHA’s more than 325,000 patients, but require definitive agreements and bankruptcy court approval. Vivos sees potentially multi-million-dollar AHA sleep-testing revenue beginning in 2027 if agreements are executed and the channel is implemented.
Vivos Therapeutics (VVOS) agreed to acquire an 11% fully diluted equity stake in SOD Sciences and co-ownership of its pseudohypoxia test. The deal includes a 50% undivided interest in the test and related intellectual property for 12,000 Series C Convertible Preferred shares with $12 million aggregate stated value, with no cash consideration. Conversion at $0.15 per common share represents up to 80 million shares, subject to ownership and exchange caps.
Closing is expected on or about October 15, 2026, subject to auditor concurrence, Series B holder consent and Nasdaq notification. Vivos expects an equity increase that could support Nasdaq compliance, subject to accounting review and Nasdaq assessment. The test interest carries a contractual right to 50% of contribution margin across all channels. Potential Cleveland Clinic Weston and American Health Associates collaborations require definitive agreements; test clinical utility remains to be established.
Vivos Therapeutics (VVOS) has begun restructuring to target $3.6 million in annual overhead savings starting in Q4 2026. Some measures are in place, with further cuts effective October 1; Vivos expects the full reductions during Q4.
Referrals to its Las Vegas centers rose approximately threefold from the first of June through September 27. Related revenue is expected from Q4 into 2027. Vivos projects a $1.5 million to $3.0 million annualized revenue run rate for its EEG testing and treatment initiative in Q4, up from near zero in May. Its remote patient monitoring program is expected to add annualized revenue of up to $3.5 million by Q1 2027. Vivos expects legacy payer contract rate increases to add $2.4 million to $5.6 million in revenue, with full realization expected in early 2027 and over the next six to nine months. Management targets positive cash flow by late 2026 or early 2027 and profitability in 2027.
Vivos Therapeutics (VVOS) has reduced debt under its secured promissory note with Streeterville Capital by exchanging note principal for equity as of August 31, 2026.
The company entered into twelve exchange agreements with Streeterville, swapping $2,861,270 of outstanding principal for 11,445,080 common shares at $0.25 per share. This follows an August 4, 2026 exchange of $3,250,000 of principal for 2,500 Series B Non-Convertible Preferred shares and 1,812,031 common shares. After these transactions, the Streeterville Note balance (including fees and original issue discount) is about $3.7 million, down from an original principal of $8,225,000 on June 9, 2025. The exchanges are expected to reduce liabilities and increase stockholders’ equity, supporting Nasdaq listing requirements.
Vivos Therapeutics (NASDAQ: VVOS) announced that founder and CEO R. Kirk Huntsman will present at the 2026 Moody Capital Solutions Disruptive Growth & Life Sciences Conference at The Westin New York Grand Central in New York City on September 9, 2026, at 8:45 a.m. Eastern Time. Management will also hold a Q&A session and be available for one-on-one meetings with institutional investors during the conference.
Vivos Therapeutics (Nasdaq: VVOS) signed definitive collaboration and operating agreements with South Palm Cardiovascular Associates (SPCVA) to establish and operate a regional Sleep & Airway Medicine Center (SAMC) in Palm Beach County, Florida, through a new management services organization, AIM Florida.
According to Vivos, it expects to hold a 75% majority membership and economic interest in AIM Florida, subject to regulatory and contractual terms. The parties are evaluating locations and negotiating a lease, with patient treatment and revenue generation targeted for the first quarter of 2027, pending customary startup milestones.
The initial Sleep Optimization Team is planned to serve about 250 patients per month and, based on Vivos’ Las Vegas experience and current assumptions, could generate up to $6 million in annual revenue with contribution margins of 30% or more once fully deployed. SPCVA, a cardiology practice with approximately 30,000 patients, is expected to help build referrals for comprehensive OSA testing and treatment using Vivos’ FDA‑cleared technologies.
Vivos Therapeutics (Nasdaq: VVOS) reported that average weekly new obstructive sleep apnea patient referrals into its Nevada Sleep & Airway Medicine Centers rose 212% over the past six weeks compared with the prior six weeks. Since June 1, the total average weekly number of referrals has increased nearly five-fold and has continued to grow week over week.
The company will open an 8,100 sq. ft. sleep testing and treatment facility in Henderson, Nevada, on August 27, 2026. According to Vivos, the Henderson practice, previously in a smaller space, achieved its highest total collections in two of the past three months, and the company expects revenue from Henderson operations to grow further once the new facility is fully operational.
Vivos Therapeutics (Nasdaq: VVOS) announced the grand opening of a new state-of-the-art sleep diagnostic, testing, and treatment center in Henderson, Nevada, with the official event scheduled for August 27, 2026. According to Vivos Therapeutics, this full-service facility is expected to more than double annual revenue production capacity in Henderson to over $10 million.
The center, part of the Sleep Centers of Nevada network, is planned to employ up to 30 medical and support staff and offer integrated services including diagnostic testing, clinical evaluation, and multiple FDA-cleared treatment modalities. Vivos reported that incoming referrals in the Las Vegas market have more than doubled since the May–June timeframe, and the added capacity is expected to have an immediate impact on revenue in that market.
Vivos Therapeutics (NASDAQ: VVOS) reported second quarter 2026 revenue of $5.2 million, up 35% year over year, with first-half 2026 revenue of $10.3 million, up 51%. Growth was driven by higher service revenue, mainly from sleep testing and treatment services in Nevada operations.
Gross profit rose to $3.0 million in Q2 and $6.0 million for the first half, with gross margins improving to 57% and 58%, respectively. Operating expenses increased to $7.8 million in Q2 and $17.5 million year-to-date, reflecting the SCN acquisition and new treatment centers. Vivos recorded a Q2 net loss of $5.5 million and a first-half net loss of $13.3 million. As of June 30, 2026, cash and equivalents were $1.8 million, and stockholders’ equity showed a deficit of $3.8 million. Management highlighted rising patient referrals, growing pediatric and insomnia programs, and progress toward partnerships with multi-center cardiology groups in Florida and Arizona.